TARA — Protara Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $294.30m
- $161.63m
- 47
- 27
- 83
- 51
Annual income statement for Protara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 34.4 | 47.5 | 67.1 | 43.6 | 49.2 |
| Operating Profit | -34.4 | -47.5 | -67.1 | -43.6 | -49.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -34 | -47.3 | -66 | -40.4 | -44.6 |
| Net Income After Taxes | -34 | -47.3 | -66 | -40.4 | -44.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34 | -47.3 | -66 | -40.4 | -44.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34 | -47.3 | -66 | -40.4 | -44.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.7 | -4.21 | -3.24 | -3.57 | -2.17 |